US patent for needle-free penile syringe:
This article was originally published in Clinica
Medi-Ject has received a US patent covering its needle-free syringe for delivering drugs into the penis. The new device for so-called intracorporal delivery is a modification of the company's needle-free technology which is already available commercially for the administration of insulin and growth hormones. The modified Medi-Jector system would encourage significantly more men to take advantage of erectile dysfunction therapy, said the Minneapolis, Minnesota-based company. In addition to starting Phase I/II clinical studies to assess the safety and efficacy of needle-free delivery, Medi-Ject plans to test an approved drug.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.